The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations

Journal of Virology

Volumn 80, Issue 10, 2006, Pages 4971-4977

  Parikh, Urvi M ^a   Bacheler, Lee ^b   Koontz, Dianna ^a   Mellors, John W ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VircoLab Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS RECOMBINANT;

ADENINE; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ARGININE; DIDANOSINE; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, MULTIPLE, VIRAL; GENOTYPE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LYSINE; PHENOTYPE; PHOSPHONIC ACIDS; POINT MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; THYMIDINE; ZALCITABINE; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33646440592     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.80.10.4971-4977.2006     Document Type: Article

References (49)

1. Arion, D., N. Kaushik, S. McCormick, G. Borkow, and M. A. Parniak. 1998. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′- deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37:15908-15917.
2. Bazmi, H. Z., J. L. Hammond, S. C. H. Cavalcanti, C. K. Chu, R. F. Schinazi, and J. W. Mellors. 2000. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-β-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 44:1783-1788.
3. Boyer, P. L., S. G. Sarafianos, E. Arnold, and S. H. Hughes. 2002. The M184V mutation reduces the selective excision of zidovudine 5′- monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J. Virol. 76:3248-3256.
4. Boyer, P. L., S. G. Sarafianos, E. Arnold, and S. H. Hughes. 2001. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75:4832-4842.
5. Brodard, V., H. Moret, I. Béguinot, L. Morcrette, L. Bourdaire, J. Jacques, C. Rouger, C. Strady, J.-L. Berger, and L. Andréoletti. 2005. Prevalence of detection and dynamics of selection and reversion of K65R mutation in nucleoside reverse transcriptase inhibitor-experienced patients failing an antiretroviral regimen. J. Acquired Immune Defic. Syndr. 39:250-253.
6. Chamberlain, P. P., J. Ren, C. E. Nichols, L. Douglas, J. Lennerstrand, B. A. Larder, D. I. Stuart, and D. K. Stammers. 2002. Crystal structures of zidovudine- or lamivudine-resistant human immunodeficiency virus type I reverse transcriptases containing mutations at codons 41, 184, and 215. J. Virol. 76:10015-10019.
7. Delaunay, C., F. Brun-Vezinet, R. Landman, G. Collin, G. Peytavin, A. Trylesinski, P. Flandre, M. Miller, D. Descamps, and the Tonus Trial Study Group. 2005. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J. Virol. 79:9572-9578.
8. Deval, J., K. L. White, M. D. Miller, N. T. Parkin, J. Courcambeck, P. Halfen, B. Selmi, J. Boretto, and B. Canard. 2004. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J. Biol. Chem. 279:509-516.
9. Foli, A., K. M. Sogocio, B. Anderson, M. Kavlick, M. W. Saville, M. A. Wainberg, Z. Gu, J. M. Cherrington, H. Mitsuya, and R. Yarchoan. 1996. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]-adenine (PMEA). Antivir. Res. 32:91-98.
10. Gallant, J. E., A. E. Rodriguez, W. G. Weinberg, B. Young, D. S. Berger, M. L. Lim, Q. Liao, L. Ross, J. Johnson, and M. S. Shaefer, for the ESS30009 Study. 2005. Early virological nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J. Infect. Dis. 192:1921-1930.
11. Garcia-Lerma, J. G., H. MacInnes, D. Bennett, P. Reid, S. Nidtha, H. Weinstock, J. E. Kaplan, and W. Heneine. 2003. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J. Virol. 77:5685-5693.
12. Gotte, M., D. Arion, M. A. Parniak, and M. A. Wainberg. 2000. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type I impairs rescue of chain-terminated DNA synthesis. J. Virol. 74:3579-3585.
13. Gu, Z., E. Arts, M. Parniak, and M. Wainberg. 1995. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type I shows diminished chain termination in the presence of 2′,3′- dideoxycytidine 5′-triphosphate and other drugs. Proc. Natl. Acad. Sci. USA 92:2760-2764.
14. Gulick, R. M., H. J. Ribaudo, C. M. Shikuma, S. Lustgarten, K. E. Squires, W. A. Meyer, E. P. Acosta, B. R. Schackman, C. D. Pilcher, R. L. Murphy, W. E. Maher, M. D. Witt, R. C. Reichman, S. Snyder, K. L. Klingman, and D. R. Kuritzkes. 2004. Triple nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. 350:1850-1861.
15. Hammond, J. L. 2000. Investigation of the structural features of human immunodeficiency virus reverse transcriptase inhibitors that influence the selection of resistance mutations. Ph.D. thesis. University of Pittsburgh, Pittsburgh, Pa.
16. Hammond, J. L., U. M. Parikh, D. L. Koontz, S. Schlueter-Wirtz, C. K. Chu, H. Z. Bazmi, R. F. Schinazi, and J. W. Mellors. 2005. In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine. Antimicrob. Agents Chemother. 49:3930-3932.
17. Harrigan, P. R., T. Mo, B. Wynhoven, J. Hirsch, Z. Brumme, P. McKenna, T. Pattery, J. Vingerhoets, and L. T. Bacheler. 2005. Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 19:549-554.
18. Hoogewerf, M., R. Regez, W. Schouten, H. Weigel, P. Frissen, and K. Brinkman. 2003. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet 362:1979-1980.
19. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
20. Johnson, V. A., F. Brun-Vezinet, B. Clotet, B. Conway, D. R. Kuritzkes, D. Pillay, J. Schapiro, A. Telenti, and D. D. Richman. 2005. Update of the drug resistance mutations in HIV-1: 2005. Top. HIV Med. 13:51-57.
21. Kagan, R. M., T. C. Merigan, M. A. Winters, and P. N. Heseltine. 2004. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization. Antivir. Ther. 9:827-828.
22. Khanlou, H., V. Yeh, B. Guyer, and C. Farthing. 2005. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDs 19:135-140.
23. Lanier, E., N. Givens, C. Stone, P. Griffin, D. Gibb, S. Walker, M. Tisdale, D. IrIbeck, M. Underwood, M. St. Clair, and M. Ait-Khaled. 2004. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Med. 5:394-399.
24. Leon, A., E. Martinez, J. Mallolas, M. Laguno, J. L. Blanco, T. Pumarola, and J. M. Gatell. 2005. Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. AIDS 19:213-215.
25. Marcelin, A.-G., C. Delaugerre, M. Wirden, P. Viegas, A. Simon, C. Katlama, and V. Calvez. 2004. Thymidine analogue reverse transcriptase inhibitor resistance mutation profiles and association to other nucleoside reverse transcriptase inhibitor resistance mutations observed in the context of virological failure. J. Med. Virol. 72:162-165.
26. Meyer, P. R., S. E. Matsuura, A. M. Mian, A. G. So, and W. A. Scott. 1999. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4:35-43.
27. Meyer, P. R., S. E. Matsuura, D. Zonarich, R. R. Chopra, E. Pendarvis, H. Z. Bazmi, J. W. Mellors, and W. A. Scott. 2003. Relationship between 3′-azido-3′-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 77:6127-6137.
28. Miller, M. D., N. A. Margot, D. J. McColl, T. Wrin, D. F. Coakley, and A. K. Cheng. 2003. Characterization of resistance mutation patterns emerging over 2 years during first-line antiretroviral treatment with tenofovir DF or stavudine in combination with lamivudine and efavirenz. Antivir. Ther. 8:S151.
29. Naeger, L. K., N. A. Margot, and M. D. Miller. 2002. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 49:3355-3360.
30. Parikh, U. M., D. L. Koontz, C. K. Chu, R. F. Schinazi, and J. W. Mellors. 2005. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob. Agents Chemother. 49:1139-1144.
31. Podzamczer, D., E. Ferrer, J. M. Gatell, J. Niubo, D. Dalmau, A. Leon, H. Knobel, C. Polo, D. Iniguez, and I. Ruiz. 2005. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antivir. Ther. 10:171-177.
32. Roge, B. T., T. L. Katzenstein, N. Obel, H. Nielsen, O. Kirk, C. Pedersen, L. Mathiesen, J. Lundgren, and J. Gerstoft. 2003. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir. Ther. 8:173-182.
33. Sarafianos, S. G., K. Das, J. Ding, P. L. Boyer, S. H. Hughes, and E. Arnold. 1999. Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Chem. Biol. 6:R137-R146.
34. Segondy, M., and B. Montes. 2005. Prevalence and conditions of selection of the K65R mutation in the reverse transcriptase gene of HIV-1. J. Acquired Immune Defic. Syndr. 38:110-111.
35. Selmi, B., J. Boretto, S. R. Sarfati, C. Guerreiro, and B. Canard. 2001. Mechanism-based suppression of dideoxynucleoside resistance by K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue. J. Biol. Chem. 276:48466-48472.
36. Sharma, P. L., P. A. Chatis, A. L. Dogon, D. L. Mayers, F. E. McCutchan, C. Page, and C. S. Crumpacker. 1996. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro inhibition assay. Virology 223:365-369.
37. Shi, C., and J. W. Mellors. 1997. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 41:2781-2785.
38. Sluis-Cremer, N., D. Arion, N. Kaushik, H. Lim, and M. A. Parniak. 2000. Mutational analysis of Lys65 of HIV-1 reverse transcriptase. Biochem. J. 348:77-82.
39. Stone, C., M. Ait-Khaled, C. Craig, P. Griffin, and M. Tisdale. 2004. Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine. Antimicrob. Agents Chemother. 48:1413-1415.
40. Valer, L., L. Martin-Carbonero, C. de Mendoza, A. Corral, and V. Soriano. 2004. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations. AIDS 18:2094-2096.
41. Wainberg, M. A., M. D. Miller, Y. Quan, H. Salomon, A. S. Mulato, P. D. Lamy, N. A. Margot, K. E. Anton, and J. M. Cherrington. 1999. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir. Ther. 4:87-94.
42. Weber, J., B. Chakraborty, J. Weberova, M. D. Miller, and M. E. Quinones-Mateu. 2005. Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J. Clin. Microbiol. 43:1395-1400.
43. White, K. L., N. A. Margot, J. K. Ly, J. M. Chen, A. S. Ray, M. Pavelko, R. Wang, M. McDermott, S. Swaminathan, and M. D. Miller. 2005. A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS 19:1751-1760.
44. Winston, A., S. Mandalia, D. Pillay, B. Gazzard, and A. Pozniak. 2002. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients. AIDS 16:2087-2089.
45. Winston, A., A. Pozniak, S. Mandalia, B. Gazzard, D. Pillay, and M. Nelson. 2004. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase? AIDS 18:949-951.
46. Wirden, M., A.-G. Marcelin, A. Simon, M. Kirstetter, R. Tubiana, M. A. Valantin, L. Paris, M. Bonmarchand, F. Conan, L. Kalkias, C. Katlama, and V. Calvez. 2005. Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients. J. Med. Virol. 76:297-301.
47. Wolf, K., H. Walter, N. Beerenwinkel, W. Keulen, R. Kaiser, D. Hoffmann, T. Lengauer, J. Selbig, A.-M. Vandamme, K. Korn, and B. Schmidt. 2003. Tenofovir resistance and resensitization. Antimicrob. Agents Chemother. 47:3478-3484.
48. Yahi, N., J. Fantini, M. Henry, C. Tourres, and C. Tamalet. 2005. Structural analysis of reverse transcriptase mutations at codon 215 explains the predominance of T215Y over T215F in HIV-1 variants selected under antiretroviral therapy. J. Biomed. Sci. 12:701-710.
49. Zhang, D., A. M. Caliendo, J. J. Eron, K. M. DeVore, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1994. Resistance to 2′,3′- dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:282-287.